(Q36979311)

17 August 2017

1 reference

https://doi.org/10.1080/14656566.2019.1643067

1 reference

29 December 2023

title

Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate (English)

1 reference

17 August 2017

Jun Iwamoto

1

1 reference

17 August 2017

Tsuyoshi Takeda

series ordinal

2

1 reference

17 August 2017

Yoshihiro Sato

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

16

1 reference

17 August 2017

page(s)

2743-2756

1 reference

Osteoporosis prevention, diagnosis, and therapy

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Molecular mechanisms of action of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

THE METABOLIC EFFECTS OF STEROID HORMONES IN OSTEOPOROSIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

The effect of estrogen deficiency on calcium balance in mature rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Calcium plus vitamin D supplementation and the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Daily and cyclic parathyroid hormone in women receiving alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Pathogenesis of bone fragility in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Treatment of male osteoporosis: recent advances with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Corticosteroids and fractures: a close encounter of the third cell kind.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Use of oral corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Management of the adverse effects associated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2743

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

New developments in the pathogenesis and treatment of steroid-induced osteoporosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Male osteoporosis: new trends in diagnosis and therapy

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Unresolved issues in osteoporosis in men.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Distribution of oestradiol receptor molecules in human kidney

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Calcium and vitamin D for corticosteroid-induced osteoporosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Etanercept for the treatment of rheumatoid arthritis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Evidence for estrogen receptor-linked calcium transport in the intestine

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Adenovirus-mediated gene therapy of osteoblasts in vitro and in vivo

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Estrogen and bone metabolism

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1517/14656566.8.16.2743

Identifiers

DOI

10.1517/14656566.8.16.2743

1 reference

17 August 2017

1 reference